As­traZeneca stocks up on Calquence am­mu­ni­tion for big BTK ri­val­ry with J&J, Ab­b­Vie

6 years ago
R&D

In a blow to sci­ence, Trump ad­min­is­tra­tion aborts fed­er­al fund­ing for fe­tal tis­sue re­search

6 years ago
R&D

The FDA is forc­ing a small an­tibi­ot­ic play­er back to the clin­ic for a new tri­al — 10 years af­ter first re­jec­tion

6 years ago
R&D
FDA+

Third Rock rais­es a record $770M to back its own brand of biotech star­tups — while 1 key part­ner ex­its

6 years ago
Startups

Take­da suf­fers an­oth­er set­back in its quest to ex­pand myelo­ma drug’s reach — and block­buster po­ten­tial

6 years ago
R&D

Pfiz­er scoops Cal­i­co ex­ec Jeff Set­tle­man to head big on­col­o­gy R&D ops in La Jol­la

6 years ago

For­eign threats to NIH re­search: Sen­ate Fi­nance Com­mit­tee digs in

6 years ago
China

Clock starts tick­ing on Leif Jo­hansson's re­tire­ment from As­traZeneca chair­man role — re­port

6 years ago
People

Deer­field strikes up new deal with Co­lum­bia Uni­ver­si­ty; Ovid CEO Je­re­my Levin joins BIO as new board chair

6 years ago
News Briefing

Ned Sharp­less weighs in on gene ther­a­py pric­ing de­bate, sug­gest­ing 'the mes­sag­ing got lost'

6 years ago
People
Cell/Gene Tx

Mid-stage da­ta on Al­lena's hy­per­ox­aluria drug fu­el op­ti­mism ahead of piv­otal read­out

6 years ago
R&D

In­flaRx shares shat­tered as lead drug flops bad­ly in a PhI­Ib tri­al while Chemo­Cen­tryx is caught in the smash up

6 years ago
R&D
Pharma

Bris­tol-My­ers bumps off chief sci­en­tist in an­oth­er big shake­up, bring­ing in Cel­gene and No­var­tis ex­ecs

6 years ago
People
Pharma

Texas biotech Lung Ther­a­peu­tics clos­es $36M Se­ries C to ad­vance clin­i­cal work for or­phan drugs

6 years ago
R&D

Where Te­va failed, Eli Lil­ly gained — mi­graine drug Em­gal­i­ty wins US ap­proval for episod­ic clus­ter headaches

6 years ago
R&D

The Wash­ing­ton Post points the fin­ger at Pfiz­er for stay­ing mum about an Alzheimer’s study. But there’s more to ...

6 years ago
Bioregnum
Pharma

Spread­ing its wings in Chi­na with glob­al am­bi­tion, EpimAb snags $74M Se­ries B for bis­pe­cif­ic work

6 years ago
Financing
China

Cel­gene/Ac­celeron win speedy FDA re­view for lus­pa­ter­cept in be­ta tha­lassemia; Ko­re­an in­vestor out to shake up ...

6 years ago
News Briefing

Neil Wood­ford force­ful­ly stems in­vestor out­flow by sus­pend­ing his be­lea­guered main fund

6 years ago
People
Financing

Bay­er en­lists Arv­inas on two-pronged pro­tein degra­da­tion ef­fort, for­ay­ing in­to agtech

6 years ago

Weeks af­ter rais­ing $40M, Cel­gene-part­nered In­hi­brx lays ground­work for near­ly $75M pub­lic de­but

6 years ago
Financing

Mer­ck tests an­tibi­otics wa­ters again as FDA OKs Zer­bax­a's ex­pand­ed use in pneu­mo­nia

6 years ago
Pharma

#AS­CO19: MET in­hibitors from In­cyte/No­var­tis and Ger­many's Mer­ck face off for rare sub­set of NSCLC pa­tients

6 years ago
R&D

Add one fa­tal flaw to Jiankui He's litany of mis­takes in CRISPR ba­by de­ba­cle

6 years ago
People
Discovery
First page Previous page 928929930931932933934 Next page Last page
A service from the Financial Times